RCAP
CYTK icon

Resolute Capital Asset Partners’s Cytokinetics CYTK Stock Holding History

Resolute Capital Asset Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-65,000
Closed -$4.13M – 47
2025
Q4 		$4.13M Buy
65,000
+5,000
+8% +$311K 2% 19
2025
Q3 		$3.3M Buy
+60,000
New +$2.47M 1.73% 21

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Resolute Capital Asset Partners's CYTK Position: Q1 2026 in Review

Resolute Capital Asset Partners sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 65,000 shares — an estimated $4.13M sold.

Resolute Capital Asset Partners first reported a position in CYTK in Q3 2025 and held it in 2 quarters. The position peaked at $4.13M in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Resolute Capital Asset Partners reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
  • Resolute Capital Asset Partners sold 65,000 Cytokinetics shares in Q1 2026, an estimated $4.13M.
  • Resolute Capital Asset Partners first reported a position in Cytokinetics in Q3 2025 and held it in 2 quarters.
  • Resolute Capital Asset Partners's Cytokinetics position peaked at $4.13M in Q4 2025.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Resolute Capital Asset Partners's 13F filing for Q1 2026, filed 15 May 2026.